Showing results (301-310 of 1,900) with videos related to
Sort By:
Pageof 190
Journal of Hazardous Materials|September 30, 2010
Biodegradation of dibutyl phthalate and di-(2-ethylhexyl) phthalate and microbial community changes in mangrove sedimentShaw-Ying Yuan, I-Chun Huang, Bea-Ven ChangBMC Bioinformatics|May 28, 2016
Identification of recurrent focal copy number variations and their putative targeted driver genes in ovarian cancerLiangcai Zhang, Ying Yuan, Karen H Lu, et al.Biometrics|May 13, 2022
A Bayesian platform trial design to simultaneously evaluate multiple drugs in multiple indications with mixed endpointsYujie Zhao, Rui Sammi Tang, Yeting Du, et al.Statistics in Medicine|April 24, 2018
Comparative review of novel model-assisted designs for phase I clinical trialsHeng Zhou, Thomas A Murray, Haitao Pan, et al.Journal of Hazardous Materials|November 8, 2008
Anaerobic degradation of nonylphenol in subtropical mangrove sedimentsBea-Ven Chang, Zhong-Jun Lu, Shaw-Ying YuanFundamental & Clinical Pharmacology|July 9, 2010
Neuroprotective effects of ultra-low-molecular-weight heparin in vitro and vivo models of ischemic injuryZhi-guo Zhang, Tai-sheng Lü, Hong-ying YuanJournal of Clinical Medicine|May 27, 2026
Successful Staged Surgery for Esophagopulmonary Fistula with Lung Abscess During Neoadjuvant ChemoradiotherapyMu-Chou Lin, Wei-Lun Chang, Ying-Yuan ChenPharmaceutical Statistics|May 16, 2014
A Bayesian dose-finding design for drug combination clinical trials based on the logistic modelMarie-Karelle Riviere, Ying Yuan, Frédéric Dubois, et al.Pharmaceutical Statistics|February 3, 2015
Phase I trial design for drug combinations with Bayesian model averagingIck Hoon Jin, Lin Huo, Guosheng Yin, et al.Biometrics|September 10, 2024
A Bayesian latent-subgroup platform design for dose optimizationRongji Mu, Xiaojiang Zhan, Rui Sammi Tang, et al.Pageof 190